Recent Articles from Business Wire

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance.

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Center’s Department of Medical Oncology at the 2025 European Society of Medical Oncology (ESMO) Annual Congress.

Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the company’s Phase 1/2 CLARA trial, which evaluated the safety, efficacy and tolerability of AURN001 (neltependocel [human corneal endothelial cells] in combination with Y-27632 rho-kinase inhibitor) in patients with corneal edema secondary to corneal endothelial dysfunction. The findings were presented at Cornea Day during the American Academy of Ophthalmology (AAO) meeting in Orlando, FL.

Houston’s Energy Day Festival returned for its 13th year of energy, education, excitement and engagement on Saturday, Oct. 18 at Sam Houston Park in downtown Houston.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2025 (Presentation #LBA3).

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) in patients with a high risk of disease recurrence. The trial compared ENHERTU with trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment.

Positive results from the DESTINY-Breast05 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and a high risk of disease recurrence. Results were presented today (LBA1) alongside the results of DESTINY-Breast11 (291O) in Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy. These late-breaking data will be presented for the first time today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2025 (Presentation #LBA2) and were selected for an official Press Briefing.

Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate when compared with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2 positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. Results were presented today (291O) alongside the results from the DESTINY-Breast05 (LBA1) phase 3 trial during Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate. The trial compared ENHERTU followed by THP with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Snap Inc. (NYSE: SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the “Class Period”). Snap is a technology company best known for Snapchat.

Infrrd, a global leader in AI-driven document processing solutions, has announced the official launch of Ally, the company’s pioneering Agentic AI workforce built exclusively for the mortgage industry.

University of Phoenix College of Social and Behavioral Sciences announces a new white paper, “Trauma-Informed Education – A Pathway for Relief, Retention, and Renewal,” authored by College leadership Sheila Babendir, Ed.D., LPAC; Barbara Burt, Psy.D.; Michelle Crawford-Morrison, LMFT, LPCC, NCC; Samantha E. Dutton, Ph.D., LCSW-R; Christine Karper, Ph.D., LMHC (QCS); and MaryJo Trombley, Ph.D. The paper asserts that implementing trauma-informed practices can improve outcomes for students and educators, driving retention and well-being while equipping learners with skills they can carry into the workplace.

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, compared to chemotherapy for patients with advanced endometrial carcinoma following at least one prior platinum-based regimen in any setting. The findings, based on five years of follow-up from the Phase 3 KEYNOTE-775/Study 309 trial evaluating KEYTRUDA plus LENVIMA versus chemotherapy (treatment of physician’s choice of doxorubicin or paclitaxel), for these patients with advanced endometrial carcinoma are being presented during a poster session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany (Presentation #1119P).

Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR), in heavily pretreated patients with advanced endometrial cancer (EC) who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor. Additionally, at a median study follow-up of one year, 63.6% of responders (including CRs) in the 100 mg/m² cohort maintained their responses and remain on treatment. The responses were observed regardless of FRα expression levels. The updated results were presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) originating in the lungs or thymus. These data will be presented at the 2025 European Society for Medical Oncology Congress (ESMO) during the Monday Poster Session: Neuroendocrine Tumours on October 20, 2025, from 12:00 – 12:45 p.m. CEST.

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced data from the dose escalation portion of the Phase 1/2 study of JK06, a 5T4-targeted antibody drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer, including non-small cell lung cancer (NSCLC) and breast cancer, which is being presented at the European Society for Medical Oncology (ESMO) Congress.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 44% and 62% in the intention-to-treat (ITT) and ESR1-mutated populations, respectively, compared with standard-of-care endocrine therapy plus everolimus. The evERA study is evaluating the investigational giredestrant combination in people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer previously treated with cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy. This is the first positive head-to-head Phase III trial investigating a selective estrogen receptor degrader-containing regimen versus a standard-of-care combination. The results are being presented in an oral session at the European Society for Medical Oncology Congress 2025. Data will be shared with health authorities, with the aim of bringing this potential treatment option to people as soon as possible.

Please replace the release dated October 15, 2025 with the following corrected version due to multiple revisions.

Light & Wonder, Inc. (NASDAQ and ASX: LNW) (“Light & Wonder,” “L&W,” “we” or the “Company”) is providing an update on today’s ruling from the Nevada Court regarding the ongoing litigation with Aristocrat.

U-Haul® Company of Alaska has made all of its 11 Company facilities across the state available to provide 30 days of free self-storage and U-Box® container usage to support displaced residents after Typhoon Halong destroyed many Native communities along the western coast.

Kolibri Global Energy Inc. (the “Company” or “Kolibri“) (TSX: KEI, NASDAQ: KGEI) wishes to provide an update to certain information contained in the management information circular and related materials (the “Circular”) filed on October 15, 2025 in connection with a special meeting of shareholders (the “Meeting”) called by the Company in response to a shareholder requisition made on behalf of TFG Asset Management UK LLP, the purpose of which is to vote on altering the Notice of Articles of the Company to cap the number of common shares of the Company (“Shares”) that the Company is authorized to issue at 37,367,894 (the “Proposed Resolution”).

The Law Offices of Frank R. Cruz announces an investigation of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors concerning the Company’s possible violations of federal securities laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors concerning the Company’s possible violations of the federal securities laws.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Brunello Cucinelli S.p.A (OTC: BCUCY) resulting from allegations that Brunello Cucinelli may have issued materially misleading business information to the investing public.

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI), if they purchased the Company’s securities between February 26, 2025 to August 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 20, 2025 to file lead plaintiff applications in a securities class action lawsuit against Snap Inc. (NYSE: SNAP), if they purchased the Company’s securities between April 29, 2025 to August 5, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

Asteria, the next-gen film and animation studio, today announced ALL HEART, a new animated short film written and directed by Academy Award® winners Michael Govier & Will McCormack, the filmmaking duo behind the Oscar-winning Netflix short If Anything Happens I Love You.

The DJS Law Group announces that it is investigating claims on behalf of investors of Grindr Inc. (“Grindr” or “the Company”) (NYSE: GRND) for potential breaches of fiduciary duty on the part of its directors and management.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brunello Cucinelli S.p.A. (“Brunello Cucinelli” or “the Company”) (OTC Markets: BCUCY) for violations of the securities laws.

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of F5, Inc. (NASDAQ: FFIV) (“F5”).

The DJS Law Group announces that it is investigating claims on behalf of investors of Brunello Cucinelli S.p.A. (“Brunello Cucinelli” or “the Company”) (OTC Markets: BCUCY) for violations of the securities laws.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Grindr Inc. (“Grindr” or “the Company”) (NYSE: GRND) for potential breaches of fiduciary duty on the part of its directors and management.

Law Offices of Howard G. Smith announces an investigation on behalf of Zions Bancorporation, National Association (“Zions” or the “Company”) (NASDAQ: ZION) investors concerning the Company’s possible violations of federal securities laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zions Bancorporation, National Association (“Zions” or the “Company”) (NASDAQ: ZION) investors concerning the Company’s possible violations of the federal securities laws.

Please replace the release with the following corrected version due to multiple revisions.

Sensient Technologies Corporation (NYSE: SXT) will hold its earnings call and webcast to discuss 2025 third quarter results at 8:30 a.m. CDT on Friday, October 31, 2025. Investors may access the live webcast on the Company’s web site at investor.sensient.com. Alternatively, investors may join the conference call by contacting Chorus Call Inc. at (844) 492-3726 or (412) 317-1078.

SameDayAbortionPills—Reproductive health providers are raising concerns as patients encounter an unexpected barrier at the pharmacy counter: occasional instances of retail pharmacists declining to dispense mifepristone (Mifeprex), an FDA-approved drug used in medication abortion.

Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.2833 per unit for the month of October 2025. The distribution will be paid by Granite on November 14, 2025 to unitholders of record at the close of trading on October 31, 2025.

Calix, Inc. (NYSE: CALX) today announced that ALLO Communications has launched Smart Schools, an innovative program built on Calix SmartTown® for Education and fully integrated with the Calix Broadband Platform. Smart Schools will provide safe, secure community Wi-Fi for Lincoln Public School (LPS) students in grades 6-12 who opt into the program—promoting digital equity and extending learning beyond the classroom.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI) resulting from allegations that Designer Brands may have issued materially misleading business information to the investing public.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Baxter International Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”). Baxter develops, manufactures, and markets medical products.

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a+” (Excellent) of AMEX Assurance Company (AMEX) (headquartered in Chicago, IL). The outlook of these Credit Ratings (ratings) is stable.

Arctera, a global leader in data management, today announced it has been positioned as a Leader in the 2025 Gartner® Magic Quadrant™ for Digital Communications Governance and Archiving Solutions (DCGA), marking the second consecutive year the company was recognized.

The Chequit, located at 23 Grand Avenue in Shelter Island Heights, today announced that the property will close for the winter season on November 2, 2025, with a scheduled reopening April 2026.

Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), is pleased to announce the acquisition of a Heartland Dental property for $3.3 million. The property is located in a highly trafficked corridor in Oklahoma and is corporate operated under a triple net lease with approximately four years of term remaining. The transaction was priced at a 6.9% cap rate including a near-term rent increase and exclusive of transaction costs.

The Boards of Directors of Flaherty & Crumrine Preferred and Income Fund Incorporated (NYSE: PFD), Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated (NYSE: PFO), Flaherty & Crumrine Preferred and Income Securities Fund Incorporated (NYSE: FFC), Flaherty & Crumrine Total Return Fund Incorporated (NYSE: FLC) and Flaherty & Crumrine Dynamic Preferred and Income Fund Incorporated (NYSE: DFP) today announced that they have declared per share dividends for November 2025 as detailed below:

Delek Logistics Partners, LP (NYSE: DKL) (“Delek Logistics”) today announced that the Partnership intends to issue a press release summarizing third quarter 2025 results before the U.S. stock market opens on Friday, November 7, 2025. A conference call to discuss these results is scheduled to begin at 11:00 a.m. CT (12:00 p.m. ET) on Friday, November 7, 2025.

Delek US Holdings, Inc. (NYSE: DK) (“Delek US”) today announced that the Company intends to issue a press release summarizing third quarter 2025 results before the U.S. stock market opens on Friday, November 7, 2025. A conference call to discuss these results is scheduled to begin at 9:30 a.m. CT (10:30 a.m. ET) on Friday, November 7, 2025.

RiverNorth Opportunities Fund, Inc. and RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. are each pleased to announce the declaration of preferred dividends for the fourth quarter of 2025, as detailed below.

Intelligent power management company Eaton (NYSE:ETN) will announce third quarter 2025 earnings on Tuesday, November 4, 2025, before the opening of the New York Stock Exchange. The company will host a conference call at 11 a.m. Eastern time that day to discuss third quarter 2025 earnings results.

KBRA assigns a long-term rating of AA+ to the North Slope Borough, AK General Obligation Bonds, Series 2025. KBRA additionally affirms the long-term rating of AA+ for the Borough's outstanding general obligation bonds. The rating Outlook is Stable.

The Law Offices of Frank R. Cruz announces an investigation of Zions Bancorporation, National Association (“Zions” or the “Company”) (NASDAQ: ZION) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1 mg) compared with a sham procedure that mimics intravitreal (IVT) injections in people with uveitic macular edema (UME). UME is characterized by the buildup of fluid in the macula due to uveitis, an inflammatory condition of the eye, that can result in vision loss. Across both studies, the primary and secondary endpoint data support the potential for rapid improvements in vision and reductions in macular thickness (swelling in the back of the eye due to retinal fluid) with vamikibart treatment. The data were presented at the American Academy of Ophthalmology annual meeting (AAO 2025) in Orlando, FL.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Western Alliance Bancorporation (“Western Alliance” or the “Company”) (NASDAQ: WAL) investors concerning the Company’s possible violations of the federal securities laws.

AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a complex epithelial-driven inflammatory condition. TEZSPIRE is the first and only biologic that targets thymic stromal lymphopoietin (TSLP) to be approved for CRSwNP.

Venture Global, Inc. (“Venture Global”) (NYSE: VG) announced today that it plans to issue its earnings release with respect to third quarter 2025 financial results before market open on Monday, November 10, 2025.

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that the company granted inducement equity awards covering an aggregate of 114,500 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of 65,429 shares of common stock and inducement restricted stock units, covering an aggregate of 49,071 shares of its common stock.

FuboTV Inc. (d/b/a Fubo) (NYSE: FUBO), the leading sports-first live TV streaming platform, today announced that on October 16, 2025, the Compensation Committee of Fubo’s Board of Directors granted restricted stock unit awards covering an aggregate of 74,320 shares of its common stock to 12 new employees to induce them to join Fubo. The awards were granted under Fubo’s 2025 Employment Inducement Equity Incentive Plan, and vest annually over a four-year period following their grant, subject to continued employment. The awards were granted as employment inducement awards pursuant to the New York Stock Exchange rules.

Permianville Royalty Trust (NYSE: PVL, the “Trust”) today announced a cash distribution to the holders of its units of beneficial interest of $0.030000 per unit, payable on November 14, 2025 to unitholders of record on October 31, 2025. The net profits interest calculation represents reported oil production for the month of July 2025 and reported natural gas production during June 2025. The calculation includes accrued costs incurred in August 2025.

Old Dominion Freight Line, Inc. (Nasdaq: ODFL) announced today the release of its 2024 Sustainability Report. The 2024 Sustainability Report content has been informed by the Sustainability Accounting Standards Board (SASB) Road Transportation Sustainability Accounting Standard and is reported with reference to the Global Reporting Initiative (GRI) standards. Old Dominion received a limited assurance verification opinion for its 2024 Scope 1 and Scope 2 Greenhouse Gas (GHG) Inventory from an independent third party. The 2024 Sustainability Report and GHG Inventory limited assurance verification opinion are available under the Corporate Responsibility section of the Company’s investor website at ir.odfl.com.

Comfort Systems USA, Inc. (NYSE: FIX), a leading provider of mechanical and electrical contracting services including heating, ventilation, air conditioning, plumbing, electrical, piping and controls, announces that it has scheduled its quarterly conference call and webcast for Friday, October 24, 2025, at 10:00 a.m. Central Time to discuss third quarter 2025 financial results. The results will be released after the market closes on Thursday, October 23, 2025.

Law Offices of Howard G. Smith announces an investigation on behalf of Western Alliance Bancorporation (“Western Alliance” or the “Company”) (NASDAQ: WAL) investors concerning the Company’s possible violations of federal securities laws.

Backblaze, Inc. (Nasdaq: BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, will report financial results for its third quarter ending September 30, 2025 on Thursday, November 6, 2025 before market open.

DoubleVerify (“DV”) (NYSE: DV), a leading software platform for digital media measurement, data and analytics, today announced that it will report third quarter 2025 financial results before the market opens on Friday, November 7, 2025. Management will host a conference call and webcast to discuss DV's financial results, recent developments and business outlook at 8:00 a.m. ET following the release of the financial results.

The law firm of Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake and certain of MoonLake’s executives with violations of the Securities Exchange Act of 1934.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Rezolve AI plc (NASDAQ: RZLV) resulting from allegations that Rezolve may have issued materially misleading business information to the investing public.

The Law Offices of Frank R. Cruz announces an investigation of Western Alliance Bancorporation (“Western Alliance” or the “Company”) (NASDAQ: WAL) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Western Alliance Bank’s Multifamily Housing Finance Group today announced a strategic alliance with Clover Lending Group, an integrated asset management, development and property management company specializing in affordable senior living and other multifamily communities.

Woodside Energy today announced a donation of MXN$400,000 (~US$20,000) to the Mexican Red Cross to support individuals and families affected by severe flooding in northern Veracruz and southern Tamaulipas.

Humata Health today announced plans to make its AI-powered prior authorization technology available with Microsoft Dragon Copilot. By delivering enhanced capabilities within this ambient-powered AI clinical assistant, Humata Health will enable clinicians to automate and streamline crucial prior authorization tasks, ultimately reducing provider burden and accelerating patient access to appropriate care.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Hillenbrand, Inc. (NYSE: HI) to an affiliate of Lone Star Funds. Under the terms of the proposed transaction, shareholders of Hillenbrand will receive $32.00 in cash for each share of Hillenbrand that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.